Helen Tayton-Martin

Supervisory Director

Dr. Helen Tayton-Martin has broad pharmaceutical, consulting and biotech company-building experience. She served as Chief Business & Strategy Officer of Adaptimmune plc, a commercial cell therapy developer (NASDAQ: ADAP) until March 2025, a position held since October 2022 and previously CBO from 2017. As a Co-founder of Adaptimmune, Dr Tayton-Martin was its founding COO from 2008, a role in which she oversaw the transition of operations in the company from five to 300 staff, through transatlantic growth, multiple clinical, academic and commercial collaborations and private and public financing through to IPO. Dr. Tayton-Martin was responsible for all of Adaptimmune’s strategic partnerships including those with GlaxoSmithKline, Astellas, Genentech and Galapagos NV.

Prior to her 17 years with Adaptimmune, Dr. Tayton Martin spent 15 years working within the pharma, biotech and consulting environment in disciplines across preclinical and clinical development, outsourcing, strategic planning, due diligence, business development, alliance management and company operations. She has also served as a non executive director of Trillium Therapeutics Inc. (Nasdaq and TSX: TRIL) from October 2017 through to successful sale to Pfizer Inc. in November 2021 and is a current non-executive director of Evaxion A/S (NASDAQ: EVAX), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines.

Helen holds a Ph.D. in molecular immunology from the University of Bristol, U.K. and an M.B.A. from London Business School.